NGNE · Neurogene Inc
United States · RS rating 43 · As of 2026-11-03
| Price | 26.67 USD |
|---|---|
| 1-day change | +0.2% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 60 / 25 / 35 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 22 / 30 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -10.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +37.8% |
| Market cap (USD) | $420.8M |